Search
for
Sort by
Research 91–120 of 1000+
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- Quantitative evaluation of carcinosin as an individualized remedy in pediatric alopecia areata using salt score and ludwig hair loss scales: A case report
- An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Alopecia Universalis: Never Give Up?
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
- Oral Baricitinib Restores Hair Loss in Alopecia Areata
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- What is the appropriate indication for baricitinib in patients with alopecia areata? What prior options can be considered?
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
- Role of platelet rich plasma therapy in the treatment of alopecia areata and atrophic acne scars
- A Study on the Role of Tofacitinib Among Patients Treated with Alopecia Areata
- Response of alopecia areata of the beard to oral tofacitinib
- Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial
- What is the appropriate indication for baricitinib in patients with alopecia areata? What prior options can be considered?
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
- Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis
- Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta-analysis
- In reply
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Intralesional Methotrexate Is Comparable to Triamicinolone Acetonide and Superior to Vitamin D3 in the Treatment of Alopecia Areata
- Alopecia areata and ritlecitinib: Unravelling response trajectories